- Home
- NRIM vs REPL Comparison
NRIM vs REPL Comparison
Compare NRIM & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- REPL
- Stock Information
- Founded
- NRIM 1990
- REPL 2015
- Country
- NRIM United States
- REPL United States
- Employees
- NRIM N/A
- REPL N/A
- Industry
- NRIM Savings Institutions
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- NRIM Finance
- REPL Health Care
- Exchange
- NRIM Nasdaq
- REPL Nasdaq
- Market Cap
- NRIM 500.9M
- REPL 649.1M
- IPO Year
- NRIM N/A
- REPL 2018
- Fundamental
- Price
- NRIM $91.19
- REPL $9.63
- Analyst Decision
- NRIM
- REPL Strong Buy
- Analyst Count
- NRIM 0
- REPL 7
- Target Price
- NRIM N/A
- REPL $20.29
- AVG Volume (30 Days)
- NRIM 57.0K
- REPL 1.7M
- Earning Date
- NRIM 07-23-2025
- REPL 05-22-2025
- Dividend Yield
- NRIM 2.81%
- REPL N/A
- EPS Growth
- NRIM 46.48
- REPL N/A
- EPS
- NRIM 7.52
- REPL N/A
- Revenue
- NRIM $164,695,000.00
- REPL N/A
- Revenue This Year
- NRIM N/A
- REPL N/A
- Revenue Next Year
- NRIM $7.25
- REPL N/A
- P/E Ratio
- NRIM $12.13
- REPL N/A
- Revenue Growth
- NRIM 26.35
- REPL N/A
- 52 Week Low
- NRIM $52.10
- REPL $4.93
- 52 Week High
- NRIM $92.45
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- NRIM 68.06
- REPL 58.72
- Support Level
- NRIM $86.00
- REPL $8.25
- Resistance Level
- NRIM $92.45
- REPL $10.16
- Average True Range (ATR)
- NRIM 2.23
- REPL 0.92
- MACD
- NRIM -0.15
- REPL 0.21
- Stochastic Oscillator
- NRIM 80.47
- REPL 84.04
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.